RYBREVANT plus chemotherapy received European Commission approval in August 2024 for the treatment of patients with previously treated non-small cell lung cancer (NSCLC) with common EGFR mutations, based on the superior efficacy and safety profile demonstrated in the MARIPOSA-2 study.